Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-Hold BMA: Continuation vs De-escalation of Bone Modifying Agents in Bone Metastases
NCT04549207Phase 4Active, not recruiting
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Oct 2020
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in bone metastasis (2 arms), sponsored by Ottawa Hospital Research Institute. Primary endpoint: Health related quality of life scores at 48 weeks. Started Oct 2020; status: active, not recruiting.
02
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT04549207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04549207.